Full Press Release Details
Media
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.
April 14, 2025
IRWD Positive Sentiment
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
Key Takeaway: Ironwood Pharmaceuticals has provided a clinical and regulatory update regarding Apraglutide, a treatment aimed at gastrointestinal diseases. The company emphasizes its commitment to improving care standards for GI patients. This announcement highlights the progress being made in the development of Apraglutide.
Price reaction · baseline $0.9455 (2025-04-11 close) · clean, no other IRWD news in the window
day 0 close · peak
-31.5%
day 1
-23.6%
day 3
-23.1%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals is advancing treatment options for GI diseases.
- The update on Apraglutide reflects ongoing commitment to GI healthcare.
- The company aims to redefine the standard of care for GI patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is Apraglutide?
Apraglutide is a treatment developed by Ironwood Pharmaceuticals for gastrointestinal diseases.
What is the focus of Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals focuses on advancing the treatment of gastrointestinal diseases.
When was the update on Apraglutide released?
The update on Apraglutide was released on April 14, 2025.
What is Ironwood's mission?
Ironwood's mission is to redefine the standard of care for GI patients.